Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 3, 2024, reports on the interim analysis results of the DREAMM-8 Phase III clinical trial. The announcement was issued on June 2, 2024, coinciding with the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The filing focuses on the oncology therapeutic area, specifically the treatment of relapsed/refractory multiple myeloma.
Key Financial and Operational Metrics
The filing does not provide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a scientific and regulatory update regarding clinical trial efficacy and safety data.
Clinical Trial Results (DREAMM-8)
- Primary Endpoint (Progression-Free Survival - PFS): The Blenrep (belantamab mafodotin) combination reduced the risk of disease progression or death by nearly 50% compared to the standard of care (bortezomib combination). Hazard Ratio (HR): 0.52 (95% CI: 0.37-0.73), p-value <0.001.
- Median PFS: Not yet reached at 21.8 months median follow-up for the Blenrep arm versus 12.7 months for the control arm.
- 1-Year PFS Rate: 71% for the Blenrep arm versus 51% for the control arm.
- Overall Survival (OS): A positive trend was observed (HR: 0.77) but was not statistically significant at this interim analysis. 1-year survival was 83% (Blenrep) vs 76% (control).
- Response Rates: Overall Response Rate (ORR) was 77% (Blenrep) vs 72% (control). Complete Response (CR) or better rate was 40% vs 16%.
- Minimal Residual Disease (MRD) Negativity: 23.9% for Blenrep vs 4.8% for control.
Material Changes and Comparisons
The filing highlights that DREAMM-8 is the second Phase III head-to-head trial to demonstrate robust efficacy for a Blenrep combination in the second-line and later setting, following positive results from the DREAMM-7 trial announced in February 2024. The patient population in DREAMM-8 was more heavily pre-treated than in DREAMM-7, with 75% of patients being refractory to lenalidomide. The results show consistent improvements across pre-specified subgroups, including those with high-risk cytogenetics.
Outlook, Risks, and Management Commentary
Management Commentary: GSK leadership stated that the data supports the potential for Blenrep combinations to redefine the treatment of multiple myeloma at or after first relapse. The company is continuing to share data and discuss the path forward with regulators.
Safety Profile: The safety profile was consistent with known risks. Grade 3 or higher non-ocular adverse events included neutropenia (57% vs 39%), thrombocytopenia (38% vs 29%), and pneumonia (17% vs 8%). Eye-related side effects occurred in 43% of patients (Grade 3 or higher) but were generally reversible and manageable, leading to a 9% discontinuation rate.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2023 Form 20-F and Q1 2024 results. Specific risks include regulatory approval uncertainties and the ongoing nature of Overall Survival follow-up.
Key Facts for Investor Verification
- Verify the regulatory status of Blenrep in the US and EU markets following these positive Phase III results.
- Monitor the final Overall Survival (OS) data, as the interim analysis showed a positive but non-significant trend.
- Assess the commercial impact of Blenrep on GSK's oncology revenue stream, given the high unmet need in relapsed/refractory multiple myeloma.
- Review the long-term safety data regarding ocular adverse events to ensure they do not impact patient retention or label restrictions.
- Confirm the timeline for potential regulatory submissions based on the "path forward" discussions mentioned by management.